The IL-15 superagonist complex N-803 (formerly termed ALT-803) induces potent activation of NK cells and has been shown to be safe when administered alone and in combination with the anti-CD20 antibody rituximab in patients with indolent non-Hodgkin lymphoma [52, 53]. The gene discussed is IL15; the disease is non-Hodgkin lymphoma.